|
En Espanol 
|
Pronunciation(kal si TRYE ole)
U.S. Brand NamesCalcijex®; Rocaltrol®
Synonyms1,25 Dihydroxycholecalciferol
Generic AvailableYes
Canadian Brand NamesRocaltrol®
UseManagement of hypocalcemia in patients on chronic renal dialysis; management of secondary hyperparathyroidism in moderate-to-severe chronic renal failure; management of hypocalcemia in hypoparathyroidism and pseudohypoparathyroidism
Use - Unlabeled/InvestigationalDecrease severity of psoriatic lesions in psoriatic vulgaris; vitamin D resistant rickets
Pregnancy Risk FactorC (manufacturer); A/D (dose exceeding RDA recommendation) (expert analysis)
LactationEnters breast milk/not recommended
ContraindicationsHypercalcemia; vitamin D toxicity; abnormal sensitivity to the effects of vitamin D; pregnancy (dose exceeding RDA)
Warnings/PrecautionsAdequate dietary (supplemental) calcium is necessary for clinical response to vitamin D. Monitor serum calcium and phosphate concentrations; avoid hypercalcemia; calcium-phosphate product (serum calcium times phosphorus) must not exceed 70. Immobilization or excessive dosage may increase risk of hypercalcemia and/or hypercalciuria. Maintain adequate hydration. Use caution in patients with malabsorption syndromes (efficacy may be limited and/or response may be unpredictable).
Adverse Reactions>10%: Endocrine & metabolic: Hypercalcemia (33%) Frequency not defined: Cardiovascular: Cardiac arrhythmia, hyper-/hypotension Central nervous system: Headache, irritability, seizure (rare), somnolence, psychosis Dermatologic: Pruritus, erythema multiforme Endocrine & metabolic: Hypermagnesemia, hyperphosphatemia, polydipsia Gastrointestinal: Anorexia, constipation, metallic taste, nausea, pancreatitis, vomiting, xerostomia Hepatic: LFTs increased Neuromuscular & skeletal: Bone pain, myalgia, dystrophy, soft tissue calcification Ocular: Conjunctivitis, photophobia Renal: Polyuria
Overdosage/ToxicologyToxicity rarely occurs from acute overdose. Symptoms of chronic overdose include hypercalcemia, hypercalciuria with weakness, altered mental status, GI upset, renal tubular injury, and occasionally cardiac arrhythmias. Following withdrawal of the drug, treatment consists of bed rest, liberal fluid intake, reduced calcium intake, and cathartic administration. Severe hypercalcemia requires I.V. hydration and forced diuresis. I.V. saline may increase excretion of calcium. Calcitonin, cholestyramine, prednisone, sodium EDTA, biphosphonates, and mithramycin have all been used successfully to treat the more resistant cases of vitamin D-induced hypercalcemia. Use of peritoneal dialysis against a calcium-free dialysate has been reported.
Drug InteractionsInduces CYP3A4 (weak)Cholestyramine, colestipol: May decrease absorption/effect of calcitriol. Corticosteroids: May decrease hypercalcemic effect of calcitriol. Digitalis: Risk of toxicity may be increased due to hypercalcemia from calcitriol. Monitor. Magnesium-containing antacids: Toxicity may be increased by calcitriol. Avoid concurrent use. Thiazide diuretics: May increase risk of hypercalcemia.
StabilityStore in tight, light-resistant container; calcitriol degrades upon prolonged exposure to light
CompatibilityStable in D5W, NS, sterile water for injection
Mechanism of ActionPromotes absorption of calcium in the intestines and retention at the kidneys thereby increasing calcium levels in the serum; decreases excessive serum phosphatase levels, parathyroid hormone levels, and decreases bone resorption; increases renal tubule phosphate resorption
Pharmacodynamics/KineticsOnset of action: ~2-6 hours Duration: 3-5 days Absorption: Oral: Rapid Protein binding: 99.9% Metabolism: Primarily to 1,24,25-trihydroxycholecalciferol and 1,24,25-trihydroxy ergocalciferol Half-life elimination: 3-8 hours Excretion: Primarily feces; urine (4% to 6%)
DosageIndividualize dosage to maintain calcium levels of 9-10 mg/dLRenal failure: Children: Oral: 0.25-2 mcg/day have been used (with hemodialysis); 0.014-0.041 mcg/kg/day (not receiving hemodialysis); increases should be made at 4- to 8-week intervals I.V.: 0.01-0.05 mcg/kg 3 times/week if undergoing hemodialysis Adults: Oral: 0.25 mcg/day or every other day (may require 0.5-1 mcg/day); increases should be made at 4- to 8-week intervals I.V.: 0.5 mcg/day 3 times/week (may require from 0.5-3 mcg/day given 3 times/week) if undergoing hemodialysis Hypoparathyroidism/pseudohypoparathyroidism: Oral (evaluate dosage at 2- to 4-week intervals): Children: <1 year: 0.04-0.08 mcg/kg once daily 1-5 years: 0.25-0.75 mcg once daily Children >6 years and Adults: 0.5-2 mcg once daily Vitamin D-dependent rickets: Children and Adults: Oral: 1 mcg once daily Vitamin D-resistant rickets (familial hypophosphatemia): Children and Adults: Oral: Initial: 0.015-0.02 mcg/kg once daily; maintenance: 0.03-0.06 mcg/kg once daily; maximum dose: 2 mcg once daily Hypocalcemia in premature infants: Oral: 1 mcg once daily for 5 days Hypocalcemic tetany in premature infants: I.V.: 0.05 mcg/kg once daily for 5-12 days Elderly: No dosage recommendations, but start at the lower end of the dosage range Dosage adjustment for toxicity: Hypercalcemia: Adults: Dialysis or hypoparathyroidism: Discontinue calcitriol and calcium supplements; initiate low-calcium diet. In dialysis patients with persistent hypercalcemia, may dialyze against calcium-free dialysate. Predialysis: Discontinue or reduce calcium supplements. If taking calcitriol 0.5 mcg once daily, reduce to 0.25 mcg once daily. If taking calcitriol 0.25 mcg once daily, discontinue until serum calcium normalizes. Restart at 0.25 mcg every other day.
AdministrationMay be administered without regard to food. Give with meals to reduce GI problems. May be administered as a bolus dose I.V. through the catheter at the end of hemodialysis.
Monitoring ParametersMonitor symptoms of hypercalcemia (weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, cramps, diarrhea, muscle pain, bone pain and irritability). If patient becomes hypercalcemic on therapy, check serum calcium daily until normalized, then twice weekly on new dose. If hypercalcemia persists in predialysis patient, monitor PTH.
Reference RangeCalcium (serum) 9-10 mg/dL (4.5-5 mEq/L) but do not include the I.V. dosages; phosphate: 2.5-5 mg/dL
Test InteractionsIncreased calcium, cholesterol, magnesium, BUN, AST, ALT, calcium (S), cholesterol (S); decreased alkaline phosphatase
Dietary ConsiderationsMay be taken without regard to food. Give with meals to reduce GI problems.
Patient EducationTake exact dose as prescribed; do not increase dose. Maintain recommended diet and calcium supplementation. Avoid taking magnesium-containing antacids. You may experience nausea, vomiting, loss of appetite, or metallic taste (small, frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); or hypotension (use caution when rising from sitting or lying position or when climbing stairs or bending over). Report chest pain or palpitations; acute headache; skin rash; change in vision or eye irritation; CNS changes; unusual weakness or fatigue; persistent nausea, vomiting, cramps, or diarrhea; or muscle or bone pain. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to become pregnant. Breast-feeding is not recommended.
Dental Health: Effects on Dental TreatmentKey adverse event(s) related to dental treatment: Metallic taste and xerostomia (normal salivary flow resumes upon discontinuation).
Dental Health: Vasoconstrictor/Local Anesthetic PrecautionsNo information available to require special precautions
Mental Health: Effects on Mental StatusMay cause sedation or irritability
Mental Health: Effects on Psychiatric TreatmentNone reported
Dosage FormsCapsule (Rocaltrol®): 0.25 mcg, 0.5 mcg [each strength contains coconut oil] Injection, solution: 1 mcg/mL (1 mL); 2 mcg/mL (2 mL) Calcijex®: 1 mcg/mL (1 mL) Solution, oral (Rocaltrol®): 1 mcg/mL (15 mL) [contains palm seed oil]
ReferencesLetsou AP and Price LS, "Health Aging and Nutrition: An Overview,"Clin Geriatr Med, 1987, 3(2):253-60. Myrianthopoulos M, "Dietary Treatment of Hyperlipidemia in the Elderly,"Clin Geriatr Med, 1987, 3(2):343-59. Riggs BL and Melton LJ, "The Prevention and Treatment of Osteoporosis,"N Engl J Med, 1992, 327(9):620-7.
International Brand NamesAcuode® (CL); Alpha D!3® (RO); Altrical® (MX); Bocatriol® (AT, DE, DK); Calcijex® (AT, AU, BD, CH, CZ, ES, GB, HK, HR, HU, ID, IL, IT, LU, NL, NO, PL, RO, SE, SG, SI, TR); Calcitriol® (AR, CH, CO); Calcitriol KyraMed® (DE); Calcitriol-Nefro® (DE); Calcitriolo Teva® (IT); Calcitriol Purissimus® (AR); Decostriol® (DE); Dexiven® (AR); Difix® (IT); Hitrol® (ID); Kalcytriol® (PL); Kolkatriol® (ID); Lotravel® (AR); Osteo D® (SI); Osteotriol® (DE); Renatriol® (DE); Rexamat® (AR); Rocaltrol® (AT, AU, BD, BE, BR, CA, CH, CL, CZ, DE, DK, ES, FR, GB, HK, HR, HU, ID, IE, IT, JP, LU, MX, NL, NO, NZ, PL, PT, RO, RU, SE, SG, SI, TH, TR, YU, ZA); Roical® (SG); Rolsical® (IN); Silkis® (BE, CH, DE, FI, FR, GB, IE, NO, PL); Sitriol® (AU); Tirocal® (MX)
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.  |
